Influence of ethanol on the pharmacokinetics of methylphenidate's metabolites ritalinic acid and ethylphenidate

Arzneimittel-Forschung/Drug Research

Volumn 60, Issue 5, 2010, Pages 238-244

  Koehm, Michaela ^a   Kauert, Gerold F ^a   Toennes, Stefan W ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

CAS 113 45 1; Ethanol, drug interaction; Genetic polymorphisms; Liquid chromatography mass spectrometry; Methylphenidate, drug interaction, metabolite kinetics

Indexed keywords

ALCOHOL; DRUG METABOLITE; ESTERASE; ETHYLPHENIDATE; METHYLPHENIDATE; RITALINIC ACID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYDROLYSIS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METABOLITE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL;

EID: 77953213990     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296279     Document Type: Article

References (36)

1. Basset-Grundy A, Butler N. Prevalence and adult outcomes of ADHD. Evidence from a 30-year prospective study. London: Bedford Group for Lifecourse and Statistical Studies, Institute of Education, University of London; 2004.
2. Levin FR, Evans SM, Kleber HD. Practical guidelines for the treatment of substance abusers with adult attention-deficit hyperactivity disorder. Psychiatr Serv. 1999;50:1001-1003
3. Barrett SP, Pihl RO. Oral methylphenidate-alcohol co-abuse. J Clin Psychopharmacol. 2002;22:633-634
4. Teter CJ, McCabe SE, Boyd CJ, Guthrie SK. Illicit methylphenidate use in an undergraduate student sample: prevalence and risk factors. Pharmacotherapy. 2003;23:609-617
5. Jaffe SL. Intranasal abuse of prescribed methylphenidate by an alcohol and drug abusing adolescent with ADHD. J AmAcad Child Adolesc Psychiatry. 1991;30:773-775
6. Froimowitz M, Patrick KS, Cody V. Conformational analysis of methylphenidate and its structural relationship to other dopamine reuptake blockers such as CFT. Pharm Res. 1995;12:1430-1434
7. Sonders MS, Zhu SJ, Zahniser NR, Kavanaugh MP, Amara SG. Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants. J Neurosci. 1997;17:960-974
8. Volkow ND, Ding YS, Wang GL, Logan J, Gatley JS, Dewey S., et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in human brain. Arch Gen Psychiatry. 1995;52:456-463
9. Bourland JA, Martin DK, Mayersohn M. Carboxylesterase-mediated transesterification of meperidine (Demerol) and methylphenidate (Ritalin) in the presence of [2H6]ethanol: preliminary in vitro findings using a rat liver preparation. J PharmSci. 1997;86:1494-1496
10. Patrick KS, Kilts CD, Breese GR. Synthesis and pharmacology of hydroxylated metabolites of methylphenidate. J Med Chem. 1981;24:1237-1240 (Pubitemid 12208783)
11. Wargin W, Patrick K, Kilts C, Gualtieri CT, Ellington K,Mueller RA, et al. Pharmacokinetics of methylphenidate in man, rat and monkey. J Pharmacol Exp Ther. 1983;226:382-386 (Pubitemid 13041511)
12. Bartlett MF, Egger HP. Disposition and metabolism of methylphenidate in dog and man. Fed Proc. 1972;31:537.
13. Patrick KS, Ellington KR, Breese GR, Kilts CD. Gas chromatographic-mass spectrometric analysis of methylphenidate and p-hydroxymethylphenidate using deuterated internal standards. J Chromatogr. 1985;343:329-338
14. Perez-Reyes M. The order of drug administration: its effects on the interaction between cocaine and ethanol. Life Sci. 1994;55:541-550
15. Perez-Reyes M, Jeffcoat AR. Ethanol/cocaine interaction: cocaine and cocaethylene plasma concentrations and their relationship to subjective and cardiovascular effects. Life Sci. 1992;51:553-563
16. Markowitz JS, Logan BK, Diamond F, Patrick KS. Detection of the novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion. J Clin Psychopharmacol. 1999;19:362-366
17. Markowitz JS, DeVane CL, Boulton DW, Nahas Z, Risch SC, Diamond F, et al. Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol. Drug Metab Dispos. 2000;28:620-624 (Pubitemid 30390399)
18. Patrick KS, Straughn AB, Minhinnett RR, Yeatts SD, Herrin AE, DeVane CL, et al. Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2007;81:346-353
19. Bailey DN. Cocapropylene (propylcocaine) formation by human liver in vitro. J Anal Toxicol. 1995;19:1-4.
20. Dean RA, Christian CD, Sample RH, Bosron WF. Human liver cocaine esterases: ethanol-mediated formation of ethylcocaine. FASEB J. 1991;5:2735-2739
21. Toennes SW, Kauert GF. Importance of vacutainer selection in forensic toxicological analysis of drugs of abuse. J Anal Toxicol. 2001;25:339-343
22. Peters FT, Hartung M, Herbold M, Schmitt G, Daldrup T, Mußhoff T. Anlage zu den Richtlinien der GTFCh zur Qualitätssicherung bei forensisch-toxikologischen Untersuchungen-Validierung. Toxichem Krimtech. 2004;71:146-154
23. Redinbo MR, Bencharit S, Potter PM. Human carboxylesterase 1: from drug metabolismto drug discovery. Biochem Soc Trans. 2003;31:620-624 (Pubitemid 36750742)
24. Farré M, de la Torre R, Llorente M, Lamas X, Ugena B, Segura J, et al. Alcohol and cocaine interactions in humans. J Pharmacol Exp Ther. 1993;266:1364-1373
25. Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet. 1999;37:457-470
26. González MA, Pentikis HS, Anderl N, Benedict MF, DeCory HH, Dirksen SJ, et al. Methylphenidate bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther. 2002;40:175-184
27. Patrick KS, Caldwell RW, Ferris RM, Breese GR. Pharmacology of the enantiomers of threo-methylphenidate. J Pharmacol Exp Ther. 1987;241:152-158
28. Shaywitz SE, Hunt RD, Jatlow P, Cohen DJ, Young JG, Pierce RN, et al. Psychopharmacology of attention deficit disorder: pharmacokinetic, neuroendocrine, and behavioral measures following acute and chronic treatment with methylphenidate. Pediatrics. 1982;69:688-694
29. Jatlow P, McCance EF, Bradberry CW, Elsworth JD, Taylor JR, Roth RH. Alcohol plus cocaine: the whole is more than the sum of its parts. Ther Drug Monit. 1996;18:460-464 (Pubitemid 26264668)
30. McCance-Katz EF, Kosten TR, Jatlow P. Concurrent use of cocaine and alcohol is more potent and potentially more toxic than use of either alone - a multiple-dose study. Biol Psychiatry. 1998;44:250-259 (Pubitemid 28389710)
31. Jatlow P, Elsworth JD, Bradberry CW, Winger G, Taylor JR, Russell R, et al. Cocaethylene: a neuropharmacologically active metabolite associated with concurrent cocaine-ethanol ingestion. Life Sci. 1991;48:1787-1794
32. Patrick KS, Williard RL, VanWert AL, Dowd JJ, Oatis JE, Jr, Middaugh LD. Synthesis and pharmacology of ethylphenidate enantiomers: the human transesterification metabolite of methylphenidate and ethanol. J Med Chem. 2005;48:2876-2881
33. Williard RL, Middaugh LD, Zhu HB, Patrick KS. Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity. Behav Pharmacol. 2007;18:39-51.
34. Sun Z, Murry DJ, Sanghani SP, Davis WI, Kedishvili NY, Zou Q, et al. Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J Pharmacol Exp Ther. 2004;310:469-476
35. Jonkman LM, Verbaten MN, Boer D de, Maes RA, Buitelaar JK, Kemner C, et al. Differences in plasma concentrations of the D- and L-threo methylphenidate enantiomers in responding and non-responding children with attention- deficit hyperactivity disorder. Psychiatry Res. 1998;78:115-118
36. Swanson JM, Volkow ND. Serumand brain concentrations of methylphenidate: implications for use and abuse. Neurosci Biobehav Rev. 2003;27:615-621